ReoPro and Retavase to Restore Brain Blood Flow After Stroke


Phase 2 Results


Interim results: 29% of the pateients (n=34) had complete reperfusion within 24 hours of treatment. Complete reperfusion without complication was seen in 33% of the patients in the abciximab monotherapy group, 40% of patients in the 2.5 U reteplase group, 45% in the 5 U group, 58% in the 7.5 U group, and 50% for the patients in the 10 U group.